BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26028046)

  • 21. Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid-Lipid Conjugate.
    Sakurai Y; Kato A; Hida Y; Hamada J; Maishi N; Hida K; Harashima H
    J Pharm Sci; 2019 Oct; 108(10):3218-3224. PubMed ID: 31229434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.
    Zhong Y; Goltsche K; Cheng L; Xie F; Meng F; Deng C; Zhong Z; Haag R
    Biomaterials; 2016 Apr; 84():250-261. PubMed ID: 26851390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iodinated hyaluronic acid oligomer-based nanoassemblies for tumor-targeted drug delivery and cancer imaging.
    Lee JY; Chung SJ; Cho HJ; Kim DD
    Biomaterials; 2016 Apr; 85():218-31. PubMed ID: 26874284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Smart nanoparticles with a detachable outer shell for maximized synergistic antitumor efficacy of therapeutics with varying physicochemical properties.
    Yin T; Liu J; Zhao Z; Dong L; Cai H; Yin L; Zhou J; Huo M
    J Control Release; 2016 Dec; 243():54-68. PubMed ID: 27702595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyaluronic acid-based biopharmaceutical delivery and tumor-targeted drug delivery system.
    Huang G; Huang H
    J Control Release; 2018 May; 278():122-126. PubMed ID: 29649528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor microenvironment dual-responsive core-shell nanoparticles with hyaluronic acid-shield for efficient co-delivery of doxorubicin and plasmid DNA.
    Wang T; Yu X; Han L; Liu T; Liu Y; Zhang N
    Int J Nanomedicine; 2017; 12():4773-4788. PubMed ID: 28740384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis.
    Li W; Guo Z; Zheng K; Ma K; Cui C; Wang L; Yuan Y; Tang Y
    Int J Pharm; 2017 Dec; 534(1-2):71-80. PubMed ID: 28958879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanostructured hyaluronic acid-based materials for active delivery to cancer.
    Ossipov DA
    Expert Opin Drug Deliv; 2010 Jun; 7(6):681-703. PubMed ID: 20367530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An insight on hyaluronic acid in drug targeting and drug delivery.
    Yadav AK; Mishra P; Agrawal GP
    J Drug Target; 2008 Feb; 16(2):91-107. PubMed ID: 18274931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyaluronate tethered, "smart" multiwalled carbon nanotubes for tumor-targeted delivery of doxorubicin.
    Datir SR; Das M; Singh RP; Jain S
    Bioconjug Chem; 2012 Nov; 23(11):2201-13. PubMed ID: 23039830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyaluronic acid-based conjugates for tumor-targeted drug delivery and imaging.
    Saravanakumar G; Deepagan VG; Jayakumar R; Park JH
    J Biomed Nanotechnol; 2014 Jan; 10(1):17-31. PubMed ID: 24724496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. pH-Sensitive Coiled-Coil Peptide-Cross-Linked Hyaluronic Acid Nanogels: Synthesis and Targeted Intracellular Protein Delivery to CD44 Positive Cancer Cells.
    Ding L; Jiang Y; Zhang J; Klok HA; Zhong Z
    Biomacromolecules; 2018 Feb; 19(2):555-562. PubMed ID: 29284258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innovative therapy of ovarian cancer based on overexpression of CD44 receptor.
    Bukowska B; Marczak A
    Ginekol Pol; 2015 May; 86(5):388-91. PubMed ID: 26117979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conjugation of paclitaxel to C-6 hexanediamine-modified hyaluronic acid for targeted drug delivery to enhance antitumor efficacy.
    Chen Y; Peng F; Song X; Wu J; Yao W; Gao X
    Carbohydr Polym; 2018 Feb; 181():150-158. PubMed ID: 29253957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer.
    Nikitovic D; Kouvidi K; Kavasi RM; Berdiaki A; Tzanakakis GN
    Curr Drug Deliv; 2016; 13(4):500-11. PubMed ID: 26549038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel.
    Cho HJ; Yoon HY; Koo H; Ko SH; Shim JS; Lee JH; Kim K; Kwon IC; Kim DD
    Biomaterials; 2011 Oct; 32(29):7181-90. PubMed ID: 21733572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of hyaluronic acid-based micelles and polyethylene glycol-based micelles on reversal of multidrug resistance and enhanced anticancer efficacy in vitro and in vivo.
    Wang J; Li Y; Wang L; Wang X; Tu P
    Drug Deliv; 2018 Nov; 25(1):330-340. PubMed ID: 29350064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inclusion complex from cyclodextrin-grafted hyaluronic acid and pseudo protein as biodegradable nano-delivery vehicle for gambogic acid.
    Ji Y; Shan S; He M; Chu CC
    Acta Biomater; 2017 Oct; 62():234-245. PubMed ID: 28859900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
    Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
    J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Supramolecular Complex of Methyl-β-cyclodextrin with Adamantane-Grafted Hyaluronic Acid as a Novel Antitumor Agent.
    Elamin KM; Yamashita Y; Higashi T; Motoyama K; Arima H
    Chem Pharm Bull (Tokyo); 2018 Mar; 66(3):277-285. PubMed ID: 29269686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.